TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Vigorous physical activity minutes per week
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Poor Ear Alone CNC Monosyllabic Word Understanding in Quiet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Poor Ear Alone Soundfield Thresholds
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stereotype Endorsement Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Group Preference Score
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Inclusion Score
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Total cholesterol, LDL-C, HDL-C, and triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Hemoglobin A1c (HbA1c) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: longitudinal change in neuroimaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: longitudinal measures of clinical performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: SARS-COV-2 RNA detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change in CU-Quality of Life Questionnaire Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Number of participants with Treatment-Emergent Adverse Events (TEAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Reduction of daily average crying time
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Visual analogue scale - neck pain and radiculopathy
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Mean Daily Step Count
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Longitudinal Change of Brain Network Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ocular surface staining score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Beck Suicidal Ideation Scale total scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Amyloid beta concentration in cerebrospinal fluid (CSF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean 24-Hour Urine Total Protein Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Prevalence of immune mediated disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Cardiorespiratory capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Long-term clinical outcome after surgical and medical treatment of PA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Long-term biochemical outcome after surgical treatment of PA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glenohumeral and scapulothoracic angles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Youth Urine Drug/Alcohol Screens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sleep scheduling variability
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: sleep heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: covariance between objective sleep measures and suicidal ideation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Ultrafiltration Coefficient
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cost-effectiveness (cost-utility)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Maximum tolerated dose (MTD) of curcumin in combination with piperine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optimal biologically active dose for curcumin in combination with piperine extract
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fractalkine serum dosage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician-Administered Posttraumatic Stress Disorder Scale (CAPS) SCORE
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Number of Participants With Treatment-emergent CPK Elevations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of use measured by visual analog scale
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Days/week mothers report reading with their infants
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Patient's adherence to the treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Asthma Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Up-regulation of GR-α receptor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effects of IL-17 and IL-4 cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Atherosclerotic vascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Depression Anxiety and Stress Scale (DASS) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Mental Health Continuum Short Form (MHC-SF) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Professional Quality of Life Scale (ProQOL) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in School-Burnout Inventory (SBI) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Revised University of California, Los Angeles (UCLA) Loneliness Scale (R-UCLA) Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in Brain Activation as Assessed by fMRI Images
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Percentage of Stuttered Syllables Produced During Speech Sample
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Systemic Inflammatory Response (C-Reactive Protein)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Systemic Inflammatory Response (Leucocytes Ratio)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative Systemic Inflammatory Response (Platelet Level)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Left Ventricular End-diastolic Volume (LVEDV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change From Baseline in Geographic Atrophy (GA) Area
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Body Composition (fat, fat-free mass and bone mineral density)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive and Negative Affect Scale (PANAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: The Centre for Epidemiologic Studies (CES-D Scale)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: The Chronic Pain Acceptance Questionnaire (CPAQ)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Chronic Pain Coping Inventory (CPCI-42)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: VIA-72
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Kellgren & Lawrence (K & L) grading system
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean artery pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Internal jugular vein distensibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Motor Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neuroplasticity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in skeletal muscle mitochondrial protein degradation peptide products
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: TSH levels measured
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Treatment-induced change in MAZ score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of Pulmonary Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Safety and Tolerability over time
Endpoint domain: Adverse events/effects
Primary endpoint: GAA enzymatic activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GAA protein expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinician-Administered PTSD Scale (CAPS) score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Muscle vascularization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Delayed Type Hypersensitivity (DTH) Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ELISpot Response to Melanoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With Anti-hepatitis B Surface Antigen (Anti-HBs) Antibody Concentrations Above Pre-defined Cut-off Values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With Positive Results for Serological Markers for Hepatitis B Infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Safe discharge prediction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prostate Specific Antigen Progression Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Rectal preservation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Vitreous hemorrhage resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early local treatment responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: skeletal muscle protein synthesis rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Periodic Leg Movement/Hour
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent of lenses with axis orientation within ±30°
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Adverse Events (NIH Grade ≥2)
Endpoint domain: Adverse events/effects
Primary endpoint: Antero-posterior stability index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of CSBMs (sub/week) from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Occurrence of Pseudomonas aeruginosa pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Time to Pseudomonas aeruginosa pneumonia
Endpoint domain: Adverse events/effects
Primary endpoint: Knee Society Score (KSS) Change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Efficacy of Modulen Diet
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety and tolerability assessed by adverse events (AEs), serious adverse events (SAEs), dose-limiting toxicity (DLT)
Endpoint domain: Adverse events/effects
Primary endpoint: CD8 T cell activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Coexpress activation markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mortality rate of NPC at 12 years
Endpoint domain: Mortality/survival
Primary endpoint: Change in caregiver involvement
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in early literacy skills
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in social skills
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Change in regulatory skills
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: FSH units per retrieved oocyte
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Blood Anti-HCV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Geometric Mean Titer (GMT) for Anti-JEV Neutralizing Antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Realization of a scan nine years after surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change From Baseline in NSAID ASAS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants in bowel cancer screening
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change from baseline in QTc interval [QTcF]
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: VLDL-apoC-III transport rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to reach maximum concentration of the analyte in plasma (tmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety and efficacy of Kaletra® monotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interleukin-6 Concentration in Peripheral Blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Changes in Cognitive Function
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Psychomotor development
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Brain Natriuretic Peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: serum C - reactive protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients With Ocular Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Patients With Targeted Grade 3 Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Revision of study device components
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients with chemotherapy regimen for adjuvant therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of patients with different chemotherapy time for adjuvant therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants with treatment-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change of CMV status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Global lumbar spine flexion range of motion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: proportion of patients reporting improvement of baseline illness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Immunity to the flu vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Score of Positive and Negative Syndrome Scale (PANSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of Brain Derived Neurotrophic Factor (BDNF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GvHD response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: 1-year treatment failure rate
Endpoint domain: Mortality/survival
Primary endpoint: Change in nasal airflow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Emboli
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Reactive hyperemia-peripheral artery tone index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Self-efficacy for Exercise
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Amyloid Positron Emission Tomography (PET) Scan
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Retention in medication-assisted treatment
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total number of opioid positive drug screens
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Retention rate of ESL treatment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: anti-3S antibodies titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Accuracy of leg length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of Hip Offset
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of PET results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agreement of PET results (Cohen K)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: C-index for predicting PFS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain on visual analogue scale (VAS 0-10)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MA self-administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MA- and cue-induced craving
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC0-∞ (Area under the concentration-time curve of the analyte in plasma over the time interval from 0 extrapolated to infinity after single dose administration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t1/2 (Terminal half-life of the analyte in plasma after single dose administration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum Vibriocidal antibody response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Responders vs Non-Responders Using SALT Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Successful testicular sperm retrieval
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Percentage change in insulin resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ipsilateral stroke
Endpoint domain: Mortality/survival
Primary endpoint: Change in the Dutch Gait scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in MoCA
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in ICIQ UI-SF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Kiefer Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in SF12 v 2.0 Health Survey
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in BESS Score from baseline to 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in CTSIB Score from baseline to 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in DGI Score from baseline to 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Allergen Specific IgE Rise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: functional mandibular movement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: bone density change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comparison of brace treatment outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Comparison of surgical treatment outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Identification of predictors of the need for hip reconstructive surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in apoB48 production rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Rate of Non-relapse Mortality at 100 Days Post-transplant
Endpoint domain: Mortality/survival
Primary endpoint: Primary patency of target lesion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of Joint Bleeds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Daily total number of seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Sustained Virologic Response 12 Weeks After Cessation of Therapy (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discontinuation From Study Treatment for an Adverse Event
Endpoint domain: Adverse events/effects